Emuesiri Kohworho Umukoro
Delta State University, Abraka

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

Antihypertensive Drugs Therapy in Hypertension and Covid-19 Comorbidity Emuesiri Goodies Moke; Endurance Efe Ahama; Pere-Ebi Yabrade Toloyai; Mamerhi Taniyohwo Enaohwo; Ekuerhare Basil; Emuesiri Kohworho Umukoro; Anthony Taghogho Eduviere; Ikuesirioghene Udumebraye; Choice Udufowe
Biology, Medicine, & Natural Product Chemistry Vol 12, No 1 (2023)
Publisher : Sunan Kalijaga State Islamic University & Society for Indonesian Biodiversity

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.14421/biomedich.2023.121.191-196

Abstract

The novel coronavirus (CoV) severe acute respiratory syndrome (SARS)-CoV-2 outbreak began at the end of 2019 in Wuhan, China, and has spread to over 200 countries. Many comorbidities have shown to be associated with the severity of the viral infection with hypertension being one of the highest rated comorbidities since loss of the ACE2 receptor due to SARS-Cov-2 infection can lead to increased blood pressure. The effects and clinical characteristics associated with the use of beta-blockers, angiotensin receptor blockers (ARB), and calcium-channel blockers (CCB) shows not to affect the outcome of covid-19, except in angiotensin converting enzyme inhibitor (ACEI) which may have negative outcomes on covid-19 infected patients. Many comorbidities have shown to be associated with the severity of the viral infection.
Streptozotocin-deoxycorticosterone Acetate-induced Haematotoxicity, Hepatorenal Damage and Oxidative Stress in Diabetic-hypertensive rats: Protective Role of Losartan, Metformin and Glibenclamide Combination Therapy Emuesiri Goodies Moke; Benneth Ben-Azu; Emuesiri Kohworho Umukoro; Peace Omewomano Onyilo; Paul Chinwuba; Onos Onoriode Emoyan; Kenneth Kelechi Anachuna; Ighodaro Igbe; Eric Kelly I Omogbai
Biology, Medicine, & Natural Product Chemistry Vol 15, No 1 (2026)
Publisher : Sunan Kalijaga State Islamic University & Society for Indonesian Biodiversity

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.14421/biomedich.2026.151.993-1002

Abstract

Diabetes mellitus and hypertension frequently coexist, exacerbating organ damage. This study investigated the protective effects of combination therapy with losartan (L), metformin (M), and glibenclamide (G) against Streptozotocin-deoxycorticosterone acetate (STZ/DOCA)-induced injuries in a diabetic-hypertensive rat model. Male Wistar rats were divided into five groups: normal control, STZ/DOCA control, and three treatment groups receiving L+M (LM), L+G (LG), or L+M+G (LMG). Hematological, biochemical, oxidative stress, and histopathological analyses were performed after 8 weeks. STZ/DOCA administration induced significant hematotoxicity, hepatorenal dysfunction, and oxidative stress, evidenced by altered blood parameters, elevated liver enzymes (AST, ALT), increased urea, creatinine, and malondialdehyde (MDA), alongside reduced antioxidants (GSH, SOD). Histopathology revealed severe hepatic and renal damage. All treatments provided protection, with the LMG combination showing the most comprehensive amelioration of all measured parameters and the best preservation of liver and kidney architecture. Triple therapy with losartan, metformin, and glibenclamide demonstrated superior synergistic protection against combined diabetic-hypertensive organ damage, highlighting its potential therapeutic promise for this complex comorbidity